In a study examining the perspectives on psilocybin or magic mushrooms in Canada, nearly 80% of the participants expressed their belief that psilocybin should be medically available for distressed patients. Along the same lines, approximately two-thirds of the Canadian participants in the study concurred that psilocybin should be legally accessible for those who need it.
Besides advocating for increased accessibility of the substance, a substantial 84.8 percent of participants felt that the public health system should bear the expenses of such treatments. A majority of Canadians view psilocybin as a feasible alternative, particularly for alleviating end-of-life distress.
[toc]
Primary Takeaways:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia recognize psilocybin as a legitimate medical option for managing end-of-life existential distress.
- Magic mushrooms are perceived as safe for treating existential distress.
- Participants in two double-blind trials experienced immediate and long-lasting benefits, with effects persisting for six months or even longer.
Decoding Existential Distress
Existential distress, often synonymous with existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. It can trigger feelings of helplessness, solitude, anxiety, and a loss of purpose and meaning. This form of distress is especially prevalent in patients with life-threatening diseases, possibly leading to a wish for hastened death or suicide contemplation.
Commonly, individuals confronting terminal illnesses or significant life changes are the ones who frequently experience this type of distress. It profoundly impacts their mental health and overall life quality.
Existential therapy aims to address issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of aimlessness and existential fear. It can involve several sessions and might not prove effective for everyone.
The potential inefficiency of such therapy is a key factor driving many individuals to seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
Over the last two decades, preliminary clinical experiments have highlighted the possible benefits of psychedelic substances for treating complex mental health conditions. More specifically, psilocybin has demonstrated its ability to quickly and sustainably ease existential distress in end-of-life patients.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare professionals to procure controlled substances for their patients.
Canadian Support for Psilocybin Access
A study published in the Palliative Care Journal investigates societal views on psilocybin-assisted therapy for end-of-life care. The key data from the study includes:
| Methodology | Surveyed 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% recognize psilocybin-assisted therapy as a legitimate medical option for addressing end-of-life existential distress. 63.3% endorse the integration of psilocybin into medical treatment. 84.8% back the public health system’s provision of this therapy. 44.2% believe healthcare professionals should administer the substance without the supervision of Health Canada. |
The outcomes align with surveys from Canada, England, and Australia. The researchers highlighted the uniqueness of their study as it focuses on the use of psychoactive substances to manage existential distress in end-of-life situations.
Why Canadians Support the Use of Psilocybin
An increasing number of Canadians are favoring the use of psilocybin therapy, largely driven by the findings from reputable research institutions. The perceived safety of psilocybin mushrooms for easing existential distress is another influential factor. Subjects in various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Method | Results |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin, while a low dose was administered as an active placebo control | Immediate and enduring |
| The efficacy of the therapy is largely due to mystical experiences that elicit a sense of unity and deep emotional insights, which can last for up to six months or even longer. | ||
| Trial at New York University | 29 patients were randomly selected to either receive psilocybin or the active placebo niacin. | The results of this study closely matched those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a renewed perspective on life and death. |
| BMC Palliative Care Study | Seven doctors, four practicing nurses, four chaplains, three social workers, and a psychologist, totaling nineteen participants, were interviewed. The study aimed to better understand how palliative care professionals interpret existential distress and their views on psychedelic therapy as a potential treatment option. | Palliative care professionals believe that psychedelic-assisted therapy (PAT) has the potential to alleviate existential distress. |
Patient Experiences
Besides scientific studies, numerous patient stories also support the effectiveness of psilocybin, highlighting its positive impact on mental wellbeing and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her enlightening experience during her assisted therapy. She visualizes being on a raft, surrounded by nature, and escorted by imaginative creatures. This vision imparts to her a profound sense of interconnectedness and unity with the universe, bringing her immense peace and affirmation.
Despite availing traditional mental health support, Yokoi continued to grapple with severe anxiety and distress following her diagnosis. Psilocybin therapy restored her connection with her body and bestowed upon her a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that metastasized to her lungs. At the time of the study, she was an administrative supervisor in healthcare and self-identified as an atheist. She was also diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant decreases in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she conveyed that the experiences had infused her beliefs with a sense of purpose and tangibility.
The Experience of Brenda
Brenda, a woman in her sixties, has been diagnosed with stage I colon cancer. During her assessment, it was discovered that she had no prior experience with hallucinogens and fulfilled the diagnosis criteria for Chronic Adjustment Disorder accompanied by Anxiety.
In her therapeutic sessions, Brenda experienced the process of dying on two separate occasions. These experiences led her to perceive death not as a fear, but as an integral and beautiful part of life. She credited the study for initiating her healing journey from past childhood trauma. The data collected from her mirrored this significant transformation. Her anxiety and fear of death decreased, while her spirituality increased significantly.
Availability of Psilocybin Products in Canada
At present, access to psilocybin capsules and other similar products designed to ease existential distress or other mental health problems may be limited. However, reliable online dispensaries can be an excellent source for procuring these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origins | Native to Brazil and a few neighboring South American countries. | Located in Cambodia, specifically around the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Moderately potent; suitable for beginners. | Moderate strength; ideal for those starting out. | Highly potent; suited for those with intermediate to advanced experience. |
| Effects | Produces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Leads to an energizing and long-lasting high, minor visual distortions, increased creativity, euphoria, a smooth physical high, fractal images, and sensations of happiness. | Evokes intense shamanic experiences, vision quests, profound mystical experiences, enhanced creativity, focus, social awareness, and mood improvement. |
Mitigate End-of-life Distress with Psilocybin Products
Existential or end-of-life distress can impose a significant burden on many patients nearing the end of their lives. Conventional treatments for this distress may not always be effective, prompting increased support within Canada for easier access to magic mushrooms in public healthcare. This growing public interest could We advocate for regulatory authorities to consider the potential therapeutic use of magic mushrooms. Obtain your psychedelics and mushroom delivery from Mushroom Canada.
Frequently Asked Questions
What should patients expect during Psilocybin-Assisted Therapy?
The experiences of patients during Psychedelic-assisted therapy (PAT) can significantly vary. To ensure a positive outcome, it’s crucial to diligently prepare and adhere to certain procedures. Comprehensive screening and mental readiness are essential before ingesting the substance.
- Preparation for the Session: The therapy begins with an extensive assessment of the patient. The therapist will discuss the patient’s goals and expectations to set the intentions for the session. The therapist will also explain the potential effects and what the patient can expect during the session.
- The Session: The patient receives a carefully controlled dose of the substance in a calm, distraction-free environment to promote relaxation and self-reflection. The therapist remains present throughout to offer ongoing support and direction.
- Post-Session Integration Therapy: This therapy helps the patient interpret and assimilate their experiences. Follow-up sessions provide continuous support and counselling to reinforce the insights and changes experienced during the therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, primarily the 5-HT2A receptor. This interaction can induce alterations in perception, mood, and cognition, leading to profound shifts in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Individuals with certain mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Reads:
